Tiziana Life Sciences Ltd(TLSA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.2500
Day High1.3200
Open:1.2500
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Tiziana Life Sciences Completes Enrollment in Phase 2 INFORM-MS Trial for Intranasal Foralumab
Tipranks
Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance
Motley Fool
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Tipranks
Tiziana Life Sciences to Showcase Intranasal Foralumab Progress at Jefferies Healthcare Conference
Tipranks
Tiziana Life Sciences Completes Enrollment in Phase 2 Intranasal Foralumab MS Trial
Tipranks
Tiziana Life Sciences Reports Positive Expanded Access Data for Intranasal Foralumab in Progressive MS
Tipranks
Tiziana Life Sciences Posts Early PET Data Showing Reduced Brain Inflammation in MSA Trial of Intranasal Foralumab
Tipranks
Tiziana Life Sciences Delays Annual 20-F Filing
Tipranks
Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab
Tipranks
Tiziana Life Sciences’ Intranasal Foralumab MSA Trial Highlighted in Late-Breaking Poster at 7th World Parkinson Congress
Tipranks
Tiziana Life Sciences Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline
Tipranks
Tiziana Life Sciences’ Intranasal Foralumab MS Study Published in Leading Neurology Journal
Tipranks
Tiziana Life Sciences Raises $8.8 Million in Oversubscribed Direct Offering to Fund Phase 2 Trials
Tipranks
Tiziana Life Sciences Raises Up to $17.6 Million in Insider-Led Direct Offering to Fund Phase 2 Trials
Tipranks
Tiziana Reports Clean FDA Safety Update for Intranasal Foralumab After 37.4 Patient-Years of Exposure
Tipranks
Tiziana Life Sciences files annual safety report for intranasal foralumab
Tipranks
Tiziana Life Sciences Chair Boosts Stake to 36% with December Share Purchase
Tipranks
Tiziana Life Sciences Rings Nasdaq Closing Bell Celebrating Milestone in Biotechnology
Tipranks
Tiziana Life Sciences Doses First Patient in Critical Phase 2 Alzheimer’s Trial

Profile

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.